U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.

Approval Year

PubMed

PubMed

TitleDatePubMed
A general preparation of protected phosphoamino acids.
2012 Mar 2

Sample Use Guides

200 mcg of IPP-201101 (FORIGERIMOD) will be administered subcutaneously every 4 weeks for 24 weeks.
Route of Administration: Other
Name Type Language
FORIGERIMOD ACETATE
USAN   WHO-DD  
USAN  
Official Name English
P-140
Code English
LUPUZOR
Brand Name English
CEP-33457
Code English
Forigerimod acetate [WHO-DD]
Common Name English
FORIGERIMOD ACETATE [USAN]
Common Name English
L-TYROSINE, L-ARGINYL-L-ISOLEUCYL-L-HISTIDYL-L-METHIONYL-L-VALYL-L-TYROSYL-L-SERYL-L-LYSYL-L-ARGINYL-O-PHOSPHONO-L-SERYLGLYCYL-L-LYSYL-L-PROLYL-L-ARGINYLGLYCYL-L-TYROSYL-L-ALANYL-L-PHENYLALANYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-, ACETATE
Common Name English
P140
Code English
Code System Code Type Description
NCI_THESAURUS
C170004
Created by admin on Sat Dec 16 01:47:34 GMT 2023 , Edited by admin on Sat Dec 16 01:47:34 GMT 2023
PRIMARY
CAS
1160237-55-7
Created by admin on Sat Dec 16 01:47:34 GMT 2023 , Edited by admin on Sat Dec 16 01:47:34 GMT 2023
PRIMARY
USAN
XX-42
Created by admin on Sat Dec 16 01:47:34 GMT 2023 , Edited by admin on Sat Dec 16 01:47:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103866
Created by admin on Sat Dec 16 01:47:34 GMT 2023 , Edited by admin on Sat Dec 16 01:47:34 GMT 2023
PRIMARY
FDA UNII
YU54FAR97X
Created by admin on Sat Dec 16 01:47:34 GMT 2023 , Edited by admin on Sat Dec 16 01:47:34 GMT 2023
PRIMARY